Passionately committed to the discovery, development, and commercialization of innovative antibacterials to treat multi-drug resistant (MDR), gram-negative infections


We are a late-stage biopharmaceutical company committed to treating serious infections.

Learn more about Our Pipeline.


We are focused on the discovery and development of antibiotics to treat gram-negative infections and have developed proprietary know-how through our work on multiple antibiotic classes. 

Learn more about Our Science.